Insider Transaction Report for Lee Nisley Newcomer at Coherus Oncology, Inc.

Lee Nisley Newcomer, a director at Coherus Oncology, Inc. (CHRS), reported a series of transactions on June 5, 2026. Newcomer acquired 30,000 shares of Common Stock through restricted stock units (RSUs), with full vesting expected on June 3, 2027, contingent upon continued service. Additionally, Newcomer was granted a stock option to purchase 60,000 shares of Common Stock at an exercise price of $1.45 per share. This option vests fully on June 3, 2027, also subject to continued service. Both the RSUs and the stock option are direct holdings, with the underlying shares for the option also being Common Stock.